%20(1).png)
%20(1).jpg)
Volta Labs at AACR 2025: Showcasing Advanced Targeted Sequencing Solutions for Cancer Research
The Volta Labs team is excited to announce our participation in the American Association of Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois. As the critical driver of progress against cancer, AACR brings together scientists, clinicians, and healthcare professionals to share groundbreaking advancements in cancer science and medicine.
Addressing the Sample Prep Bottleneck in Cancer Research
Cancer research demands precision, reliability, and efficiency—particularly when it comes to sample preparation for next-generation sequencing. While sequencing technologies have made remarkable strides over the past decade, the sample preparation phase has remained largely unchanged, creating a critical bottleneck in cancer genomics workflows.
At Volta Labs, we're revolutionizing this crucial step with our Callisto™ Sample Prep System, which brings the push-button experience of a sequencer to targeted sequencing applications. Our walk-away automation dramatically reduces hands-on time while delivering superior performance, scalability, and consistency—key requirements for cancer researchers pushing the boundaries of precision oncology.
Spotlight: Targeted Sequencing for Precision Oncology
At AACR 2025, we'll be showcasing our latest advancements in hybridization capture workflows, particularly for targeted sequencing applications in cancer research. The Callisto™ Sample Prep System has been optimized to support targeted panels for somatic variant detection, liquid biopsy analysis, and comprehensive tumor profiling.
The VoltaHyb™ suite of apps and kits are specifically configured to excel with hybridization capture chemistries, ensuring robust and consistent performance across various panel sizes—from focused hotspot panels to comprehensive cancer exomes. Our technology delivers:
- Exceptional performance with <3% redo rates and even GC distribution
- Cost-effective multiplexing powered by Callisto's unique system architecture
- Miniaturized workflows that reduce reagent usage and plastic waste
- Walk-away operation with no specialized training required
Bridging Short and Long-Read Cancer Applications
Cancer genomics is increasingly utilizing a mix of established, precise, short-read sequencing platforms, paired now with a wealth of novel structural variant insights enabled by long-read sequencing. The Callisto platform uniquely supports both approaches, allowing cancer researchers to seamlessly transition between targeted hybridization capture for hotspot detection and whole genome approaches for comprehensive structural variant analysis, while delivering clinical grade sample and library prep applications.
Our recent collaboration with leading cancer research institutions has demonstrated the Callisto system's ability to maintain the highest quality standards across both methodologies, ensuring researchers can access the most appropriate technology for their specific research questions.
Visit Booth #4806 at AACR 2025
We invite all AACR attendees to visit Volta Labs at Booth #4806, where our team will be demonstrating the Callisto™ Sample Prep System and discussing how our technology can enhance your cancer research workflows. Schedule a meeting with our team to discuss your specific applications and learn how Volta Labs can help eliminate the burden of method development, improve operational flexibility, and reduce risks related to manual sample handling.
Whether your research focuses on targeted sequencing for biomarker discovery, liquid biopsy for early detection, or comprehensive tumor profiling, the Volta team is ready to help you accelerate your discoveries.
Volta Labs is a genomics applications company transforming the way biological research and analyses are performed. Our cutting-edge digital fluidics platform maximizes performance and scalability of sample preparation while providing unparalleled consistency. We're bringing the push-button experience of a sequencer to sample prep, allowing scientists to focus on what they do best—pushing the boundaries of biology.
.webp)
Introducing VoltaHyb:
Automating the Last Mile of Targeted Sequencing Workflows
The Volta Labs team is revolutionizing critical targeted sequencing workflows with the introduction of the VoltaHyb™ suite of Apps and kits for the Callisto™ Sample Prep System. Designed to enrich your targets with confidence every single time, the Callisto platform brings unmatched workflow simplicity to hybridization capture. With Callisto, users no longer need to rely on multiple lab instruments (heated blocks, magnetic racks, vortexers) or perform time-sensitive heated transfer steps - such complex steps are abstracted away from the end user. Furthermore, Callisto's unique architecture enables precise magnetic bead manipulation coupled with uninterrupted and uniform temperature control during the hybrid capture enabling consistent enrichment performance.
Callisto reduces sequencing redo rates to less than 3% while minimizing sample loss throughout the capture process. This breakthrough approach enables reliable targeted sequencing even for challenging applications where conventional tools struggle. These advantages extend across both long and short read-based hybrid capture workflows.
The scalable architecture of the Callisto system enables flexible throughput, with the capacity to process up to 96,000 exomes per year or 48,000 PacBio HiFi samples annually. Whether you're running a small research lab or a high-volume testing facility, Callisto adapts to your needs with flexible batch sizes and consistent performance.
.webp){kind=icon}
Key Benefits
of VoltaHyb for Hybridization Capture:
Reduced Sequencing Costs:
Lower sample preparation and sequencing costs by minimizing reruns (<3% redo rates).Fully Automated Workflow:
Enables complete walk-away automation for hybridization, capture, washes, and PCR setupBroad Panel Compatibility:
Works with panels of all sizes, from small targeted panels to comprehensive exomesSupport for Both Short and Long Read Applications:
Optimized protocols for both Illumina-style short-read sequencing and long-read technologies like PacBio and Oxford Nanopore
Consistent Results:
Dramatically reduced inter-operator variability and robust performance across repeated runsUniform Coverage:
Even coverage across challenging regions, including high-GC content areasMaximum Throughput: Process up to 480 exomes simultaneously with pooled libraries with flexible batching
.webp)
VoltaHyb’s Expanding App Menu
At Volta, we’re continually growing our support for hybrid capture workflows across both short- and long-read sequencing platforms.
On the short-read side, Callisto currently supports IDT xGEN v2 chemistry, as well as Twist’s standard v2 and Fast chemistries. For long-read applications, we support PacBio HiFi enrichment based on Twist’s standard v2 chemistry.
There are more Apps coming to the VoltaHyb menu, and we’re always listening to our users. If there’s a hybrid capture chemistry you’d like to see automated on Callisto, let us know—we’d love to hear from you.
for Twist, v2 standard
The revolution in genomic sample preparation is here. By bringing the push-button experience of a sequencer to targeted sequencing workflows, Volta Labs is transforming how laboratories approach hybridization capture. The choice is no longer between inconsistent manual methods and complex automation platforms that require dedicated engineering resources. With Callisto and VoltaHyb, you can achieve consistent, high-quality results without specialized training or extensive method development.
Ready to experience the difference? Contact our team today to learn how the VoltaHyb powered Hybridization Capture can enhance your targeted sequencing workflows and accelerate your discoveries.
Relevant product pages:
.webp)
VoltaPrep for Oxford Nanopore LSK114: Automation Without the Pain
The VoltaPrep for Oxford Nanopore LSK114 app delivers what laboratories have been seeking: comprehensive workflow automation that addresses the real-world requirements of applied genomics without the traditional implementation challenges.
True Walk-Away Operation
Load your samples, select the app, and walk away. The entire LSK114 protocol—from DNA end-repair through adapter ligation and cleanup—runs without manual intervention, freeing up valuable technician time for other critical projects.
.png)
Preserved Sample Quality
Callisto's digital fluidics technology provides gentle handling specifically optimized for high molecular weight DNA, ensuring the integrity essential for nanopore applications.
.png)
Consistent, Reliable Results
Eliminate the operator-to-operator variability that plagues manual protocols and the reliability issues common with traditional automation systems.
.png)
Scalable Throughput
Process anywhere from 4 to 24 samples per run, with throughput that matches the capacity of Oxford Nanopore's PromethION 24 device—enabling seamless integration into existing workflows.
.png)
Rapid Implementation
Complete library preparation in under 3 hours with minimal hands-on time, supporting the faster timelines required in applied settings without the months-long implementation typical of traditional automation.
.png)
No Method Development Required
Unlike traditional automation approaches, there's no programming, optimization, or troubleshooting required. The application is pre-validated and ready to use the day your Callisto arrives.
.png)
Cost-Effective Operation
Miniaturized reactions reduce reagent consumption while eliminating the need for expensive liquid handling infrastructure and dedicated automation engineers.
Real-World Impact for Applied Genomics
The combination of Callisto automation and Oxford Nanopore sequencing delivers what laboratories have been seeking: a way to scale advanced sequencing technologies without the traditional automation headaches. This is particularly valuable for service laboratories, clinical laboratories, and research institutions looking to incorporate nanopore sequencing into routine workflows.
"Nanopore sequencing represents a transformative approach to genomics, and we're committed to making these powerful technologies as accessible as possible," says Udayan Umapathi, founder and CEO of Volta Labs. "With our Oxford Nanopore LSK114 app, we're extending the same automation convenience that has transformed other sequencing workflows to nanopore technology. Labs can now leverage these capabilities with unprecedented ease and consistency."
Early Adoption Success
Early access partners have already begun to see significant improvements in both efficiency and library quality using the automated LSK114 workflow. The ability to consistently produce high-quality Oxford Nanopore libraries without traditional automation complexity is proving transformative for laboratories scaling their sequencing programs.
The improvements go beyond just efficiency—we're seeing substantial reductions in failed library preparations and improved consistency across different operators, critical factors for laboratories where reliability and reproducibility are paramount.
Ready to innovate with us?
related posts
Scaling Oxford Nanopore Sequencing: VoltaPrep for LSK114 Brings Automation to Applied Genomics
.png)
.png)